National Institutes of Health
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)
UpcomingDecision brief
- Who can apply
- Small BusinessGovernmentNonprofitsOtherNonprofits (preferred)Higher Education
- Award amount
- Not specified
- Deadline
- Feb 10, 2027
- Geography
- National
- Application notesHigh effort
- Federal application
- 1 award expected — competitive
- Cooperative agreement — ongoing federal oversight
Next step
Apply at Grants.gov
Focus areas
About this grant
Type 1 diabetes (T1D) is a complex disease involving interactions among many different cell types, tissues, organs and biological processes. Genetics, the environment, and lifestyle all play a role in disease development and progression. Over the past two decades, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has supported major T1D research consortia covering basic, translational, and clinical research. Each consortium has focused on different aspects of T1D, such as specific organs, stages of disease or clinical outcomes. Together, these consortia have collected large longitudinal and multimodal datasets using standardized protocols and coordinated studies. While individual consortia have improved our understanding of specific areas, combining their work offers a rare opportunity to see how different biological processes interact to drive T1D development and progression. This integrated view can answer fundamental questions about T1D biology that cannot be answered using individual datasets or studies alone. Recent advances in artificial intelligence (AI) now make it possible to integrate these complementary datasets and study T1D across various tissues, disease stages, and biological levels. Building on these resources, NIDDK will support a coordinated, milestone-driven research project to answer fundamental questions about T1D biology and accelerate the development of personalized medicine. The project will combine multimodal human pancreas and clinical datasets to better understand how biological processes interact as T1D develops and progresses. The research will generate new insights into T1D biology, help us understand the different forms and stages of T1D, identify biomarkers, and inform new approaches for disease prevention, intervention, and treatment. To support the research, the project will develop and test advanced multimodal AI models. It will also develop AI-enabled research workflows, new methods to integrate data, and privacy-preserving synthetic datasets.
Additional details
- CFDA / ALN Number
- 93.847
- Program Title
- Diabetes, Digestive, and Kidney Diseases Extramural Research
- Expected Awards
- 1
- Estimated Total Funding
- Up to $5M
- Funding Instrument
- Cooperative Agreement
- Source
- Grants.gov · View original listing
Similar grants
AmeriCorps
Fiscal Year (FY) 2027 AmeriCorps Seniors RSVP Competition
Oct 20, 2026Assistant Secretary for Preparedness and Response
Trauma Care Readiness and Coordination Cooperative Agreement
$300K – $500K21 days — Sep 18, 2026Bureau of Global Health Security and Diplomacy
Advancing Global Health
$500K – $250MFeb 14, 2027Office of National Drug Control Policy
Improving The Capacity of Tribal Communities to Identify Emerging Drug Threats
Up to $300K3 days — Aug 31, 2026Office of National Drug Control Policy
Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition
$1 – $500K3 days — Aug 31, 2026Office of National Drug Control Policy
Applied Drug Policy Research Experiences
$1 – $100K9 days — Sep 6, 2026